Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo
- Cite this article as:
- Evliyaoğlu, Y. & Burgut, R. Int Urol Nephrol (2002) 34: 351. doi:10.1023/A:1024487604631
The efficacy of doxazosin monotherapy inchronic non-bacterial prostatitis wasinvestigated in terms of urinary symptom, painand quality of life assessment versus placebo.A total of 60 men with chronic non-bacterialprostatitis were randomised to daily supplementof 4 mg doxazosin or a placebo, for 3 months.International Prostate Symptom Score (IPSS)questionnaire was self administered at theentry and at 3 months after the cessation ofthe treatment. In addition, patients were askedto complete 2-item questionnaire on painrelated symptoms of chronic prostatitis.Quality of life was assessed with a single itemincluded in IPSS.Three months after cessation of the treatmentthere was a significant difference between theoverall mean IPSS, pain and quality of lifescores of the two groups in favour ofα-blocking agent use (p = 0.001, p <0.001 and p < 0.001, respectively). Inpatients undergone doxazosin treatment;symptom, pain and quality of life statusrevealed 32.94 ± 5.27%, 36.57 ± 5.67%and 36.78 ± 4.75% overall improvement,respectively. IPSS appeared to be a valuabletool in assessing treatment outcome of chronicnon-bacterial prostatitis.